Last reviewed · How we verify
NCT06856603: OLIGO-10
OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites
Phase 2 trial testing stereotactic radiation therapy in ablative doses to each metastatic site in Metastatic Disease in 50 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | National Medical Research Radiological Centre of the Ministry of Health of Russia |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 7 February 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- stereotactic radiation therapy in ablative doses to each metastatic site
Conditions studied
- Metastatic Disease — all drugs for Metastatic Disease →
Sponsor
National Medical Research Radiological Centre of the Ministry of Health of Russia
Who can join
18 and older, any sex, with Metastatic Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Currently, the standard of care for patients with diagnosed metastatic cancer is drug therapy (chemotherapy, targeted therapy, or immunotherapy). However, the approach to oligometastatic disease (1-5 metastases) is evolving. An increasing number of de novo, persistent, and progressive oligometastatic tumors are now being treated with curative intent, with radiation therapy among the most effective treatment options, applied to metastatic sites in ablative doses. Emerging results from the SABR-COMET 3 and 5 trials, which investigate stereotactic ablative radiotherapy for patients with 1-3 and 1-5 metastatic sites, demonstrate a clear improvement in overall survival. However, patients with more than five metastases remain in a gray area. The aim of our study is to assess the safety and effectiveness of radiation treatment for patients with tumors of various localizations and 6 to 10 metastases in the bones and internal organs. Stereotactic radiation therapy will be applied to patients with persistent or progressive metastatic forms of tumors, without changing their ongoing drug therapy regimen.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06856603
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Medical Research Radiological Centre of the Ministry of Health of Russia trials
Trials by the same sponsor.
- NCT06556550 — Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care · Phase 2, PHASE3 · recruiting
- NCT07421141 — De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer · Phase 2 · active not recruiting
- NCT05046028 — Individualization of Nutritive Sensory Support Of Radiation Therapy · Phase 4 · completed
- NCT04724538 — Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19 · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06856603 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Medical Research Radiological Centre of the Ministry of Health of Russia
- Last refreshed: 4 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06856603.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing